Sisu Pharma
Dennis J. Thiele is an accomplished scientist currently serving as the Chief Scientific Officer at Sisu Pharma since 2020. Previously, Dennis held the title of George Barth Geller Distinguished Professor of Pharmacology and Cancer Biology at Duke University School of Medicine from 2003 to 2020. Prior experience includes a role as Professor of Biological Chemistry at the University of Michigan Medical School from 1987 to 2003 and a position as a Damon Runyon-Walter Winchell Cancer Research Fund Postdoctoral Fellow at the National Cancer Institute from 1984 to 1987.
This person is not in any teams
This person is not in any offices
Sisu Pharma
Sisu Pharma is dedicated to developing targeted drugs for patients with therapy-resistant Prostate Cancer. Prostate Cancer is the second most common cancer in men worldwide and there were over 1.3 million new cases of the disease globally in 2018. There are several treatments available for Prostate Cancer but none are curative and prolongedtreatment inevitably results in resistance and death. Sisu Pharma’s proprietary technology specifically targets a key protein that is critical to the survival and spread of advanced Prostate Cancer, providing desperately needed treatment for patients with no remaining options.